Skip to main content
Purple Biotech Ltd. logo

Purple Biotech Ltd. — Investor Relations & Filings

Ticker · PPBT ISIN · IL0007650166 TA Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2024-06-05 Regulatory Filings
Country IL Israel
Listing TA PPBT

About Purple Biotech Ltd.

https://purple-biotech.com/

Purple Biotech Ltd. is a clinical-stage company that develops first-in-class therapies for cancer patients. The company focuses on advancing treatments designed to overcome tumor immune evasion and drug resistance, with the goal of providing effective and durable therapeutic solutions.

Recent filings

Filing Released Lang Actions
6K-Corporate Presentation June 2024
Regulatory Filings Classification · 96% confidence The document text explicitly states '6K:Purple Biotech Corporate Presentation June 2024' and mentions that an attachment is included: '*ea020731201-6k_purplebioEDGAR1_Bannerless_isa.pdf*'. A Form 6-K is an SEC filing used by foreign private issuers to report material events. When a filing primarily serves to announce the availability of a presentation or report, and the document itself is short (2087 characters, well under the 5,000 character threshold), it aligns best with the 'Report Publication Announcement' (RPA) definition, which covers announcements regarding the release or publication of company reports. Although it is a regulatory filing (6-K), the specific function described by the 'MENU VS MEAL' rule points to RPA.
2024-06-05 English
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
Regulatory Filings Classification · 100% confidence The document is explicitly titled 'FORM 6-K' and is filed by a 'Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934'. Form 6-K is a periodic report required for foreign private issuers, often used to file material information that is otherwise required to be disclosed in the home country or to a stock exchange. The content is a press release announcing positive interim clinical trial data (Phase 2 data at ASCO 2024) for a drug candidate (CM24). This type of material, non-scheduled announcement by a foreign private issuer is typically filed on Form 6-K. Since the provided definitions do not have a specific code for Form 6-K, and the document is a regulatory filing containing material news that doesn't fit perfectly into ER (Earnings Release), IR (Interim Report), or LTR (Legal Proceedings), the most appropriate general regulatory filing category is 'Regulatory Filings' (RNS), as it serves as a catch-all for required SEC filings that don't match other specific categories, although 6-K is a specific SEC form type. However, given the nature of the content (a press release announcing clinical trial results), it is very similar to an Earnings Release (ER) or a general announcement. Since it is a formal SEC filing (6-K) containing material information, RNS is the best fit among the provided options for a non-standard report filing, though it is highly specific regulatory disclosure. Given the options, RNS (Regulatory Filings) is the most suitable fallback for a Form 6-K that isn't an Annual Report (10-K) or Quarterly Report (IR).
2024-06-03 English
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
Report Publication Announcement Classification · 98% confidence The document explicitly mentions '6K' filing format, which is an SEC filing typically used by foreign private issuers to report material events. The text states, 'Attached hereto is a report on*6K: Purple Biotech Announces Positive Late- Breaking Interim Randomized Phase 2 Data at ASCO 2024...*'. This structure—a brief announcement stating that a report (in this case, a 6K filing containing clinical data) is attached or referenced—fits the definition of a Report Publication Announcement (RPA) under the 'MENU VS MEAL' rule, as it is announcing the release of a more substantial document rather than being the substantial document itself. The document length (2307 chars) is also short, supporting the RPA classification over a full regulatory report like 10-K or IR.
2024-06-03 English
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
Earnings Release Classification · 100% confidence The document is a press release from Purple Biotech Ltd. announcing positive interim data from a Phase 2 clinical study of their drug candidate CM24, presented at the ASCO 2024 Annual Meeting. It details efficacy endpoints like Overall Survival (OS) and Progression-Free Survival (PFS) and includes specific numerical results in a table format. This content—announcing clinical trial results and key efficacy metrics—is characteristic of an Earnings Release (ER) or a general press release summarizing important operational/clinical milestones. Since it is a press release announcing specific, time-sensitive financial/operational results (clinical trial data), it fits best under the Earnings Release (ER) category, which often encompasses major operational updates beyond just quarterly revenue figures, especially for clinical-stage biotech companies. It is not a full Annual Report (10-K), a formal Audit Report (AR), or a presentation deck (IP). Given the nature of the announcement (positive data release), ER is the most appropriate fit among the provided options. Q2 2024
2024-06-01 English
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
Report Publication Announcement Classification · 98% confidence The document is very short (1998 characters) and explicitly states that it is an 'Immediate report on other matter' and that the substantive information is contained in an attached file ('Attached hereto is a report on PR: Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024...'). This structure—a brief filing announcing the publication of a more detailed report or press release—strongly indicates a Report Publication Announcement (RPA). It is not the full report itself (like ER or IR), nor is it a standard regulatory filing like 10-K or a specific transaction notice. The reference to 'PR' (Press Release) being attached confirms the nature of the announcement.
2024-06-01 English
First Quarter 2024 Financial Results and Provides Business Update
Earnings Release Classification · 99% confidence The document is explicitly titled 'FORM 6-K' and is filed by a 'Foreign Private Issuer' for the month of May 2024. The text states: 'On May 21, 2024, Purple Biotech Ltd. (the "Company" or the "Registrant") issued a press release, "Purple Biotech Reports First Quarter 2024 Financial Results" a copy of which is attached hereto as Exhibit 99.1'. This structure—a Form 6-K filing that primarily serves to submit an attached press release detailing quarterly financial results—is characteristic of an Earnings Release (ER) being furnished to the SEC via a Form 6-K. Since the core content provided is the press release announcing the 'First Quarter 2024 Financial Results' (which includes key highlights and financial tables), the most appropriate classification for the *content* being submitted is Earnings Release (ER). Although the filing mechanism is Form 6-K, the content type aligns with ER. Given the options, ER is the best fit for the substance of the announcement. Q1 2024
2024-05-21 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.